NCT05469646View on ClinicalTrials.gov

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 3, 2022

Primary Completion Date

December 20, 2022

Study Completion Date

December 27, 2022

Conditions
Healthy
Interventions
DRUG

BI 1819479

BI 1819479

DRUG

Matching placebo

Matching placebo

Trial Locations (1)

130-0004

SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05469646 - A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated | Biotech Hunter | Biotech Hunter